TrialAdvances in therapy2018

Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.

Ralph A DeFronzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.